达维塔保健（DVA）夜盘交易中股价大跌5.83%，引发市场广泛关注。
消息面上，公司发布了第二季度财报，调整后每股收益为4.02美元，超出市场预期的3.88美元，同比增长36.27%；营收35.54亿美元，同样高于预期的34.96亿美元。尽管业绩表现强劲，但公司维持全年调整后每股收益指引14.10至15.20美元不变，指引中值14.65美元低于市场一致预期的14.88美元。由于达维塔保健在第一季度和第二季度连续大幅超越预期，市场原本对公司上调全年指引抱有较高期待，此次指引维持不变被市场解读为隐含下半年盈利增速放缓的信号，从而引发了抛售压力。
此外，公司指出第二季度单次治疗收入有所下降，从上一期的417.59美元降至415.87美元，主要原因是疫情期间补贴结束后，部分患者退出了"奥巴马医改"计划。与此同时，伯克希尔·哈撒韦公司披露已出售约18.3万股达维塔保健股票，平均每股售价约199.55美元，这在一定程度上也加剧了市场的担忧情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.